Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 3:57 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1633–1656 of 2,287 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Fasted State Clear all

Conditions: Obesity, Blood Glucose, High
Interventions: Micronutrient-dense plant-rich Intervention; Behavioral
Lead sponsor: Northern Arizona University; Other
Eligibility: 18 Years and older
Enrollment: 146 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Flagstaff, Arizona

Conditions: Major Depression
Interventions: LY03005, Pristiq; Drug
Lead sponsor: Luye Pharma Group Ltd.; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 1
States / cities: Eatontown, New Jersey

Conditions: Chronic Kidney Disease, Acute Kidney Injury
Interventions: 75 mg / 6 mL VFI™; Device
Lead sponsor: FAST BioMedical; Industry
Eligibility: 19 Years to 75 Years
Enrollment: 33 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Healthy
Interventions: Reformulated OXY (oxycodone HCl), Original OxyContin® (OXY) (oxycodone HCl); Drug
Lead sponsor: Purdue Pharma LP; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 92 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007
U.S. locations: 1
States / cities: Evansville, Indiana

Conditions: Advanced MTAP-null Solid Tumors
Interventions: Anvumetostat, Docetaxel, Comparator Anvumetostat Test Tablet; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 329 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 30
States / cities: Duarte, California • Glendale, California • Oxnard, California + 24 more

Conditions: Renal Impairment, Healthy Participants
Interventions: Linzagolix; Drug
Lead sponsor: ObsEva SA; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 33 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 2
States / cities: Orlando, Florida • Saint Paul, Minnesota

Conditions: Healthy
Interventions: Ribavirin 200 mg tablets, COPEGUS™ 200 mg Tablets; Drug
Lead sponsor: Teva Pharmaceuticals USA; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 27 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003
U.S. locations: 2
States / cities: Houston, Texas

Conditions: Healthy Volunteer
Interventions: ASTX660; Drug
Lead sponsor: Astex Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 21 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Gastric Antral Vascular Ectasia, Cirrhosis, Chronic Kidney Disease
Interventions: Gastric Emptying Breath Test; Diagnostic Test
Lead sponsor: Mayo Clinic; Other
Eligibility: 19 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Blunt Trauma to Abdomen, Wounds and Injuries, Abdomen Injury, Abdominal Injury, Abdomen, Acute
Interventions: Focused Assessment with Sonography for Trauma (FAST) Examination, No Intervention: Standard of Care - Without the FAST Examination; Diagnostic Test · Other
Lead sponsor: University of California, Davis; Other
Eligibility: Up to 17 Years
Enrollment: 4,650 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 6
States / cities: Sacramento, California • Aurora, Colorado • Atlanta, Georgia + 3 more

Conditions: Healthy Volunteers
Interventions: AMG 378, Placebo; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 2
States / cities: Lake Forest, California • Overland Park, Kansas

Conditions: Type 1 Diabetes Mellitus
Interventions: Tandem t:slim X2 with Control-IQ Technology + Dexcom G6, Dexcom CGM G5, Continuous Subcutaneous Insulin Infusion; Device
Lead sponsor: University of Virginia; Other
Eligibility: 6 Years to 18 Years
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 3
States / cities: Stanford, California • Aurora, Colorado • Charlottesville, Virginia

Conditions: Healthy Male Subjects
Interventions: Savolitinib, Fluvoxamine; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: Brooklyn, Maryland

Conditions: HIV-1 Infection
Interventions: Vesatolimod, Placebo, ARV regimen; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 8
States / cities: Los Angeles, California • San Diego, California • Ft. Pierce, Florida + 5 more

Conditions: Prediabetes, Hypertension, Obesity, Cardiovascular Disease
Interventions: Not listed
Lead sponsor: Health Diagnostic Laboratory, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 1,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2018
U.S. locations: 1
States / cities: Richmond, Virginia

Conditions: Prediabetes, Prediabetic State
Interventions: Fasting Mimicking Diet; Behavioral
Lead sponsor: University of California, Irvine; Other
Eligibility: 30 Years to 65 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Irvine, California

Conditions: Metabolic Syndrome
Interventions: Not listed
Lead sponsor: University of Washington; Other
Eligibility: 35 Years to 50 Years · Female only
Enrollment: 43 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2013
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Healthy
Interventions: Reformulated OXY (Totowa) (oxycodone HCl), Reformulated OXY (Wilson) (oxycodone HCl); Drug
Lead sponsor: Purdue Pharma LP; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 55 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Vitamin D Deficiency
Interventions: cholecalciferol; Dietary Supplement
Lead sponsor: Tufts University; Other
Eligibility: 50 Years to 69 Years
Enrollment: 62 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Hypercholesterolemia
Interventions: CAT-2054, Placebo, CAT-2054-C, Atorvastatin; Drug
Lead sponsor: Catabasis Pharmaceuticals; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 118 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 1
States / cities: West Bend, Wisconsin

Conditions: Plasma Cell Myeloma, Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma, Smoldering Plasma Cell Myeloma
Interventions: Behavioral Intervention, Beta-Adrenergic Antagonist, Propranolol, Quality-of-Life Assessment, Questionnaire Administration, Resistance Training, Short-Term Fasting; Behavioral · Drug · Other
Lead sponsor: Roswell Park Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 265 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Healthy
Interventions: Citalopram HBr eq. 10 mg tablets, single dose, CELEXATM 10 mg tablets, single dose; Drug
Lead sponsor: Actavis Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 26 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003
U.S. locations: 1
States / cities: Fargo, North Dakota

Conditions: Moderate Hepatic Impairment
Interventions: Pexidartinib; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020
U.S. locations: 2
States / cities: Miami, Florida • Orlando, Florida

Conditions: Parkinson Disease
Interventions: KM-819, Placebo; Drug
Lead sponsor: FAScinate Therapeutics Inc.; Industry
Eligibility: 40 Years and older
Enrollment: 314 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2025
U.S. locations: 3
States / cities: Glendale, California • San Diego, California • Royal Oak, Michigan

Search by objective public record fields.

A Culturally-relevant Micronutrient-dense Plant-rich (mNDPR) Dietary Intervention for Native Americans

Pilot BA Study of New LY03005 vs Pristiq

FAST GFR: Pilot Study to Evaluate the Safety of the FAST GFR Test in Patients.

To Determine the Fasting Bioequivalence of Reformulated OXY Tablets and Original OxyContin® (OXY) Tablets

A Study of Anvumetostat in Participants With Advanced MTAP-null Solid Tumors (MTAPESTRY 101)

Safety and Pharmacokinetics of Linzagolix in Female Subjects With Normal and Impaired Renal Function

Ribavirin 200 mg Tablets Under Non-Fasting Conditions

Effect of Food on the Pharmacokinetics of ASTX660 in Healthy Volunteers

Prevalence of Gastric Motor Dysfunction and Upper GI Symptoms in Gastric Antral Vascular Ectasias

A Research Study of Abdominal Ultrasound (FAST) in Children With Blunt Torso Trauma

Single and Multiple Ascending Dose Study of AMG 378 in Healthy Participants

Artificial Pancreas and Remote Monitoring During a T1DM Youth Ski Camp

A Study to Assess the Effects of Fluvoxamine on Savolitinib Exposure in Healthy Male Subjects

Safety and Biological Activity of Vesatolimod in HIV-1 Infected, Virologically Suppressed Adults

Fasting Predictors of OGTT and MMTT Response

Feasibility and Preliminary Effects of Fasting-Mimicking Diet in Asian Americans With Prediabetes

Early Vascular Wall Changes by Magnetic Resonance Imaging (MRI) in Metabolic Syndrome Versus Metabolically Normal Pre-Menopausal Women: A Pilot Study

A Study to Determine the Fasting Bioequivalence of Reformulated OXY Tablets Manufactured at Two Different Facilities

The Effect of a Meal on Vitamin D Absorption

A 2-Part, Phase 1, Single and Multiple Ascending Dose Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of CAT-2054 in Healthy Subjects

Non-chemotherapeutic Interventions for the Improvement of Quality of Life and Immune Function in Patients With Multiple Myeloma

A Relative Bioavailability Study of Citalopram HBr 10 mg Tablets Under Fasting Conditions

Study of Pexidartinib in Participants With Moderate Hepatic Impairment Compared With Healthy Participants

A Study to Evaluate Safety and Efficacy of KM-819 in Healthy Adults and Participants with Parkinson's Disease